• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Revive Expands Bucillamine Patents for Nerve Agents, Infections

    PHARMIWEB

    Revive Therapeutics Updates Nerve Agent Countermeasure Study

    GLOBENEWSWIRE

    Revive Nears Completion of Nerve Agent Study in Canada

    GLOBENEWSWIRE

    Revive Therapeutics Proposes Shares for Debt Transaction

    GLOBENEWSWIRE

    Revive Therapeutics Acquires Molecular Hydrogen Program

    GLOBENEWSWIRE

    Revive Focuses On Bucillamine For Infectious Diseases

    GLOBENEWSWIRE

    Revive Therapeutics Updates On FDA Meeting For Long COVID Study

    GLOBENEWSWIRE

    Revive Updates On FDA Meeting For Long COVID Diagnostic Product

    GLOBENEWSWIRE

    Revive Requests FDA Meeting for Bucillamine Long COVID Study

    GLOBENEWSWIRE

    Revive: FDA Meeting For Long COVID Diagnostic Test Accepted

    GLOBENEWSWIRE

    Revive To Submit Type C Meeting Request with FDA for Bucillamine to Treat COVID

    GLOBENEWSWIRE

    Revive Therapeutics Explores the Use of Bucillamine for Long COVID

    GLOBENEWSWIRE

    Revive Therapeutics` experimental COVID treatment fails in late-stage study

    REUTERS

    Revive Announces Results of Ph3 Clinical Study for Bucillamine in of COVID-19

    GLOBENEWSWIRE

    Revive kills off COVID trial after dip into data foresees flop

    FIERCE BIOTECH

    Revive Provides Phase 3 Study for Bucillamine in the Treatment of COVID-19

    GLOBENEWSWIRE

    Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

    GLOBENEWSWIRE

    Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

    GLOBENEWSWIRE

    Revive Updates Bucillamine Trial for Nerve Agent Use

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.